文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

Nix-TB试验动态疗效终点分析

Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial.
PubMed 文献 · Clin Infect Dis · 2023-01-01

本研究基于Nix-TB三期试验(NCT02333799)中93名耐多药/广泛耐药结核患者的数据,采用非线性混合效应模型分析药代动力学特征、患者特征与疗效终点的关系。结果显示较高体重指数与较低的不良治疗结局发生率相关,高基线负荷患者培养稳定转阴中位时间较长,未观察到药物暴露与疗效终点之间的关系。

要点

  • 较高体重指数与较低的不良治疗结局发生率相关
  • 低基线负荷患者培养稳定转阴中位时间3个月,高基线负荷患者4.5个月
  • 未观察到任何药物的药代动力学暴露与疗效结局之间的关系

核心结论

  • 成功描述了Nix-TB试验中BPaL方案的疗效终点,高 риск表型患者培养转阴和细菌清除时间显著延迟。
  • 药代动力学暴露与药效生物标志物之间缺乏关系,为使用更低、更安全的剂量(尤其对易发生毒性的利奈唑胺)提供了可能性。

研究设计与样本

  • Nix-TB三期临床试验(NCT02333799)的药代动力学与疗效终点分析,纳入93名参与者(占总数的85%)。
  • 药代动力学数据在第2、8、16周收集,疗效终点包括治疗结局、培养稳定转阴时间和分枝杆菌生长指示管试验中的纵向至阳性时间,采用非线性混合效应模型分析。

主要发现

  • 较高体重指数与较低的不良治疗结局发生率相关。
  • 低基线负荷患者培养稳定转阴中位时间为3个月,高基线负荷患者为4.5个月。
  • 微小疾病患者较高风险表型患者的至阳性时间轨迹更陡峭。
  • 未观察到任何药物的药代动力学(药物浓度或暴露指标)与任何疗效结局之间的关系。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safer, better, and shorter treatments for multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) are an urgent global health need. The phase 3 clinical trial Nix-TB (NCT02333799) tested a 6-month treatment of MDR and XDR-TB consisting of high-dose linezolid, bedaquiline, and pretomanid (BPaL). In this study, we investigate the relationship between the pharmacokinetic characteristics of the drugs, patient characteristics and efficacy endpoints from Nix-TB. METHODS: Pharmacokinetic data were collected at weeks 2, 8, and 16. Efficacy endpoints including treatment outcomes, time to stable culture conversion, and longitudinal time to positivity in the mycobacterial growth indicator tube assay were each characterized using nonlinear mixed-effects modeling. Relationships between patient, treatment pharmacokinetics, and disease characteristics and efficacy endpoints were evaluated. RESULTS: Data from 93 (85% of the total) participants were analyzed. Higher body mass index was associated with a lower incidence of unfavorable treatment outcomes. Median time to stable culture conversion was 3 months in patients with lower baseline burden compared with 4.5 months in patients with high baseline burden. Participants with minimal disease had steeper time to positivity trajectories compared with participants with high-risk phenotypes. No relationship between any drugs' pharmacokinetics (drug concentration or exposure metrics) and any efficacy outcomes was observed. CONCLUSIONS: We have successfully described efficacy endpoints of a BPaL regimen from the Nix-TB trial. Participants with high-risk phenotypes significantly delayed time to culture conversion and bacterial clearance. The lack of a relationship between pharmacokinetic exposures and pharmacodynamic biomarkers opens the possibility to use lower, safer doses, particularly for toxicity-prone linezolid. CLINICAL TRIALS REGISTRATION: NCT02333799.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Solans BP, Imperial MZ, Olugbosi M, et al. Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial. Clin Infect Dis. 2023. PMID: 36804834. doi:10.1093/cid/ciad051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。